Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Preferred Stock Liabilities (2019 - 2020)

C4 Therapeutics has reported Preferred Stock Liabilities over the past 2 years, most recently at $256.5 million for Q3 2020.

  • For Q3 2020, Preferred Stock Liabilities rose 25552.0% year-over-year to $256.5 million; the TTM value through Sep 2020 reached $256.5 million, up 25552.0%, while the annual FY2019 figure was $111.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q3 2020 was $256.5 million at C4 Therapeutics, up from $141.0 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $256.5 million in Q3 2020 and troughed at $1.0 million in Q3 2019.